<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04146623</url>
  </required_header>
  <id_info>
    <org_study_id>CODA01-002</org_study_id>
    <nct_id>NCT04146623</nct_id>
  </id_info>
  <brief_title>Safety Study of Live Attenuated Influenza Vaccine, CodaVax, Delivered Via Intranasal Spray</brief_title>
  <official_title>A Randomized Double-Blind, Placebo Controlled, Phase I Study of the Safety, Tolerability and Immunogenicity of a Live Attenuated H1N1 Vaccine in Healthy Individuals</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Codagenix, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Codagenix, Inc</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is being conducted to assess the safety, tolerability, and immunogenicity of the
      live-attenuated CodaVax-H1N1 influenza vaccine as compared to normal saline placebo both
      administered via intranasal spray to healthy adults.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 7, 2019</start_date>
  <completion_date type="Anticipated">September 2020</completion_date>
  <primary_completion_date type="Anticipated">September 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reactions to vaccine</measure>
    <time_frame>6 days</time_frame>
    <description>Number of solicited local and systemic reactions for CodaVax-H1N1 and placebo</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse events (AEs)</measure>
    <time_frame>30 days</time_frame>
    <description>Number of subjects with AEs for CodaVax-H1N1 and placebo</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serious adverse events (SAEs)</measure>
    <time_frame>180 days</time_frame>
    <description>Number of subjects with SAEs for CodaVax-H1N1 and placebo</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>HAI antibody titers against A/California/07/2009</measure>
    <time_frame>Day 0 and 30</time_frame>
    <description>Geometric mean titers (GMT) of anti-A/California/07/2009 (H1N1) antibodies (Hemagglutination inhibition, HAI) for each treatment arm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Increase in HAI titer against A/California/07/2009</measure>
    <time_frame>Day 0 and 30</time_frame>
    <description>Geometric mean fold increase (GMFI) of anti-A/California/07/2009 (H1N1) HAI serum antibodies for each treatment arm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HAI sero-response</measure>
    <time_frame>Day 0 and 30</time_frame>
    <description>The proportion of participants, regardless of sero-status, within each treatment arm who experience an H1N1 CA/07/2009 specific sero-response post-dose. Sero-response is defined as a ≥4-fold rise in HAI titer from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum IgG response</measure>
    <time_frame>Day 0 and 30</time_frame>
    <description>The proportion of participants within each treatment arm with a greater or equal to 2-fold rise in serum lgG antibody responses to whole virus CA/07/2009 by ELISA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Increase in serum IgG</measure>
    <time_frame>Day 0 and 30</time_frame>
    <description>Geometric mean fold increase (GMFI) within each treatment arm in serum lgG antibody responses to whole virus CA/07/2009 by ELISA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum IgA response</measure>
    <time_frame>Day 0 and 30</time_frame>
    <description>The proportion of participants within each treatment arm with a greater or equal to 2-fold rise in serum lgA antibody responses to whole virus CA/07/2009 by ELISA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Increase in serum IgA</measure>
    <time_frame>Day 0 and 30</time_frame>
    <description>Geometric mean fold increase (GMFI) within each treatment arm in serum lgA antibody responses to whole virus CA/07/2009 by ELISA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Salivary IgA Response</measure>
    <time_frame>Day 0 and 30</time_frame>
    <description>The proportion of participants within each treatment arm with a greater or equal to 2-fold rise in salivary lgA antibody responses to whole virus CA/07/2009 by ELISA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Increase in salivary IgA</measure>
    <time_frame>Day 0 and 30</time_frame>
    <description>Geometric mean fold increase (GMFI) within each treatment arm in salivary lgA antibody responses to whole virus CA/07/2009 by ELISA</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">33</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>Normal Saline Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Saline (0.9%)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CodaVax-H1N1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Live-attenuated influenza vaccine</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CodaVax-H1N1 influenza vaccine</intervention_name>
    <description>CodaVax-H1N1, a live attenuated vaccine (LAIV) strain based on the A/California/07/2009 (H1N1) influenza virus, administered once intranasally via a sprayer at a dose of 8 x10^5 plaque forming units (PFU).</description>
    <arm_group_label>CodaVax-H1N1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Normal Saline Placebo</intervention_name>
    <description>Saline (0.9%) administered intranasally via sprayer</description>
    <arm_group_label>Normal Saline Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Adult volunteers, aged 18 to 45 years (at the time of screening) in good general
             health in the opinion of the Medical Investigator or delegate, with no significant
             medical history and no clinically significant abnormal findings at screening.

          2. Participants must use highly effective, double contraception from the Screening Visit
             and up to the Follow-up Visit (Day 30).

          3. Must be willing to comply with the following conditions to prevent the spread of
             Genetically modified organisms (GMO) according the Office of Gene Technology Regulator
             (OGTR) Licence (DIR 144):

               1. Hygiene measures intended to prevent interpersonal transmission of study drug
                  must be implemented, including but not limited to frequent handwashing with soap
                  or hand disinfectant, respiratory hygiene and cough etiquette within 7 days
                  following vaccination

               2. Blood, tissue or organs must not be donated within 7 days of vaccination

               3. Severely immunosuppressed persons who require a protective environment are not to
                  be cared for by the participant within 7 days of vaccination

               4. Contact is not to be made with severely immunosuppressed persons who require a
                  protective environment within 7 days of vaccination

               5. All tissues and materials used to collect respiratory secretions are to be sealed
                  in a primary container and placed within a secondary container so that it is not
                  accessible to children or animals for 7 days until it is returned to the study
                  site for disposal, for 7 days within vaccination

          4. Contact is not to be made with infants &lt;6 months of age within 7 days of vaccination.

          5. Adequate venous access in the left or right arms to allow collection of a number of
             blood samples.

          6. Must be sero-susceptible ≤10 hemagglutination inhibition (HAI) titre to CA/07/2009
             Influenza virus (pre-screen).

          7. Laboratory Testing:

               1. Full blood examination and biochemistry within the laboratory defined normal
                  range unless deemed not clinically significant by the investigator, however a
                  small drop below the normal range for Absolute Neutrophil Count (ANC) may be
                  acceptable as per investigator discretion;

               2. Urinalysis: Negative urine glucose, negative or trace urine protein, negative or
                  trace urine hemoglobin (if trace hemoglobin is present on dipstick, a microscopic
                  urinalysis within institutional range)

          8. Able to communicate effectively with study personnel and considered reliable, willing
             and cooperative in terms of compliance with the protocol requirements

          9. Participant does not intend to start or change an existing physical conditioning
             regimen prior to or during the study period

         10. Participant has voluntarily given written informed consent to participate in the study
             (prior study entry)

         11. Participant is available for the duration of the study

        Exclusion Criteria:

          1. Immunodeficiency (including HIV) or autoimmune disorder, or participant is currently
             taking drugs (excluding steroids, see exclusion criteria 16) or was undergoing a form
             of treatment within 3 months prior to study entry that affects the immune system, or
             participant is living with somebody with the same

          2. Participant is not to have had Guillain-Barre Syndrome

          3. Received blood or blood products in the 3 months prior to screening

          4. Received another vaccine within 30 days before screening

          5. Received another influenza vaccine from 2016 to present year

          6. Participants with plans to travel to the Northern Hemisphere during the Screening
             period

          7. Participated in another clinical study (involving any investigational product or
             device) within 60 days before screening

          8. Suffered previous anaphylactic reaction to foods, vaccines, drugs or hymenoptera
             stings, or has a history of severe allergic reactions (e.g. clinically severe
             urticaria, asthma)

          9. Participants with active asthma or a history of childhood asthma which was treated
             with corticosteroids.

         10. Participants with a known egg allergy

         11. If female, pregnant, planning to become pregnant, or lactating, or participants is
             living with somebody who is pregnant or lactating.

         12. Participant has a history of, or current evidence at the time of screening of abuse of
             alcohol or any drug substance, licit or illicit, or current alcohol consumption is &gt; 4
             standard drinks (or equivalent) per day

         13. History of any psychiatric illness or psychological disorder which may impair the
             ability to provide written informed consent or participate in the study

         14. Current or history of significant neurological, cardiovascular, pulmonary (including
             asthma), hepatic, rheumatic, autoimmune, hematological, metabolic or renal disorder

         15. Clinically significant abnormal laboratory value at screening as determined by the
             Investigator

         16. Known or suspected impairment/alteration of immune function, including: Chronic use of
             oral steroids (equivalent to 20 mg/day prednisone ≥12 weeks /≥2 mg/kg body weight /
             day prednisone ≥2 weeks) within 60 days prior to Day 0 (use of inhaled, IN, or topical
             corticosteroids is allowed, unless used for the management of asthma - see exclusion
             criteria 9). Receipt of parenteral steroids (equivalent to 20 mg/day prednisone ≥12
             weeks /≥2 mg/kg body weight/day prednisone ≥ 2 weeks) within 60 days prior to Day 0.
             Or participant is living with somebody with the same

         17. Unusual dietary habits and excessive or unusual vitamin intake likely, in the opinion
             of the Investigator, to affect safety parameters

         18. Participant is sero-positive to hepatitis C virus or hepatitis B virus.

         19. Body temperature (oral) ≥38.0ºC or acute illness within 5 days prior to vaccination

         20. Any other significant finding that, in the opinion of the Investigator, would increase
             the risk of the individual having an adverse outcome from participating in this study

         21. Participant is a member of the team or is related or in a dependent relationship with
             a member of the study team, as defined as the Sponsor or study site personnel
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Q-Pharm Pty Limited</name>
      <address>
        <city>Brisbane</city>
        <state>Queensland</state>
        <zip>4006</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>October 28, 2019</study_first_submitted>
  <study_first_submitted_qc>October 29, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 31, 2019</study_first_posted>
  <last_update_submitted>June 8, 2020</last_update_submitted>
  <last_update_submitted_qc>June 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>live-attenuated vaccine</keyword>
  <keyword>influenza vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

